Need Help?
Copied to clipboard!

NCTN: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer (RTOG-0521)

Study ID: RTOG-0521

NCT Number: NCT00288080

NRG Oncology

Submitted in collaboration with the NCTN/NCORP Data Archive

Trial Title: NCTN: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCTR/IMRT followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer (RTOG-0521)

Trial Description:

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may fight prostate cancer by lowering the amount of androgens the body makes. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving hormone therapy and radiation therapy together with chemotherapy is more effective than giving hormone therapy together with radiation therapy in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying hormone therapy and radiation therapy followed by docetaxel and prednisone to see how well it works compared to hormone therapy and radiation therapy in treating patients with localized prostate cancer.

Clinical data presented in the following publication(s):

Disease type(s): Reproductive System Neoplasm, Male - Prostate Cancer

Clinical Dataset(s) included:

You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).